| ||||
 |
Site Map | Contact Us |
|||
| Home | About Us | Technologies | Product Pipeline | Media Center |
Our Board of Directors
Seth Berkley, M.D.
Seth Berkley, M.D., president and founder of the International AIDS Vaccine Initiative, is a medical doctor specializing in infectious disease, epidemiology and international health. Dr. Berkley is also an adjunct Professor of Public Health at Columbia University and an adjunct Professor of Medicine at Brown University. He received his undergraduate and medical degrees from Brown University and trained in Internal Medicine at Harvard University. He has worked for the Center for Infectious Diseases of the U.S. Centers for Disease Control, the Massachusetts Department of Public Health, and for the Carter Center, where he was assigned as an epidemiologist at the Ministry of Health in Uganda. The author of over 85 publications, he has written extensively on infectious disease, participating as a core team member in writing the World Bank’s 1993 World Development Report on Health. He was also featured on the cover of Newsweek on their 20th Anniversary issue of the discovery of the AIDS epidemic.
Philippe Chambon, M.D., Ph.D.
Phillipe Chambon, is a Managing Director and founder of New Leaf Venture Partners, LLC (NLV Partners). NLV Partners recently came about with the spin-off of the healthcare team from The Sprout Group. Prior to NLV, Philippe was a General Partner at Sprout which he joined in 1995. He has been a founding investor in five companies, and led multiple later stage investments and one buy-out. He is an active investor in all three sectors of interest for NLV. In addition to serving on VaxInnate’s board of directors, Philippe serves on the boards of directors of Artisan Pharma, Auxilium Pharmaceuticals, Aureon Biosciences, BioRelix, ePocrates and NxStage Medical. His prior investments include Cephalon, Focus Technologies, Sapient Health Network (WebMD), Charles River Laboratories and Combichem. Immediately prior to joining Sprout, Philippe was a Manager in the healthcare practice of the Boston Consulting Group. Previously, Philippe was an executive with Sandoz Pharmaceutical for seven years, where he built and led an organization responsible for late stage clinical project management, portfolio management, and pre-marketing activities. He conducted graduate research in molecular immunology at The Pasteur Institute. He earned an MD and PhD from the University of Paris, and an MBA from Columbia University.
R. Gordon Douglas, M.D.
R. Gordon Douglas, M.D., is Director of Strategic Planning at the National Institutes of Health, Dale and Betty Bumpers Vaccine Research Center. Dr. Douglas retired in April 1999 from Merck & Co., Inc., where he had been President of the Merck Vaccine Division since 1991, and a member of the Merck Management Committee. Prior to joining Merck in 1989, Dr. Douglas was a physician and academician. He received his medical staff training at The New York Hospital and Johns Hopkins Hospital and is Board Certified in Internal Medicine. His teaching and administrative affiliations included Baylor College of Medicine, University of Rochester School of Medicine, and Cornell University Medical College. He has served as a visiting professor at a number of medical schools and as a consultant to several pharmaceutical and biomedical companies. Dr. Douglas holds a bachelor's degree from Princeton University and an M.D. degree from Cornell University Medical College.
Augustine Lawlor
Mr. Lawlor has fifteen years operating experience in the biotechnology industry in finance, business development, mergers and acquisitions, and general management. Before joining HealthCare Ventures, he was Chief Operating Officer of LeukoSite, Inc. Before joining LeukoSite, Mr. Lawlor was Chief Financial Officer and Vice President of Corporate Development for Alpha-Beta Technology. He was previously Chief Financial Officer and Vice President of Business Development of BioSurface Technology. Mr. Lawlor is a member of the Board of Directors of Aton Pharma, Inc., in Tarrytown, NY; Dynogen Pharmaceuticals, Inc., in Boston, MA; GlobeImmune, Inc., in Aurora, CO; Replidyne, Inc., in Louisville, CO; the Slater Center in Providence, RI; Upstate Group, Inc., in Charlottesville, VA and U. S. Genomics, Inc., in Woburn, MA; He received a Master’s Degree in Management from Yale University. He joined HCV in 2000.
Michael Lytton, J.D., M.Sc
Mr. Lytton serves on the Boards of Directors of Alantos, Decision Biomarkers, Enanta, GPC Biotech, Rib-X, Santhera, and VaxInnate. Mr. Lytton was also responsible for investments by Oxford in Aveo, Concentric, and Radius. Mr. Lytton is Chairman of the Research and Technology Committee of the Center for Blood Research, Harvard Medical School, where he is also a member of the Board of Trustees. Mr. Lytton also serves on the Boards of Directors of two non-profit organizations, Medicines in Need, a Harvard-based foundation sponsoring clinical development of a novel drug delivery technology to be used for medicines supplied to developing world countries, and the Wildlife Trust, the leading funder worldwide of the field of conservation medicine, which studies how to stem the spread of disease in wildlife and thereby prevent its transmission to humans. In addition, he serves on the Advisory Committee to Connecticut Innovations, a public agency funding early-stage biomedical companies in Connecticut. Mr. Lytton writes a quarterly column on issues facing early-stage biomedical companies for Start-Up magazine, published by Windhover Information. Mr. Lytton has served on the Executive Board of the MIT Enterprise Forum and the Patent Committee of the Boston University Medical Center. He was a summa cum laude graduate of The Woodrow Wilson School of Public and International Affairs, Princeton University and a recipient of a Fulbright Scholarship for study at the University of London, and he received a J.D. degree cum laude from Harvard Law School. Mr. Lytton also received a M.Sc. degree in Epidemiology and Medical Statistics from the London School of Hygiene and Tropical Medicine.
Seth Rudnick, M.D.
Seth Rudnick joined Canaan in 1998 as a Venture Partner focusing on healthcare investments. He became a General Partner in 2000. His background in the healthcare industry includes comprehensive experience in research, development, clinical trials analysis and biotechnology, as well as founding and growing start-up companies in the industry. Seth currently sits on the boards of Adlyfe, Orthocon, Sopherion, and Spine Wave. Prior to joining Canaan, Seth served as CEO and Chairman at CytoTherapeutics (CTII). Before that, he helped start and served as head of R&D for Ortho Biotech, a division of Johnson & Johnson. In that role, he led the development efforts for a portfolio of projects which are still responsible for significant Johnson and Johnson revenues. He began his industrial career at Schering-Plough where he ran clinical trials for the alpha interferon project, and later transferred to Biogen to run that company's pharmaceutical development efforts. His academic career began when he served on the medical and public health faculty at Chapel Hill. Seth is a Clinical Professor of Medicine at Chapel Hill where he teaches and advises the faculty on biotechnology issues. Recently, Seth was included in the 2006 Midas List, a prominent venture capital listing which ranks the best dealmakers in high-tech and life sciences.
Franklin H. Top, Jr., M.D.
Dr. Top is Medical Director of MedImmune, Inc. Since he joined MedImmune at its inception in 1988, he has served as Executive Vice President and a member of its Board of Directors through 2003. From 1987 to 1988, Dr. Top was Senior Vice President for Clinical and Regulatory Affairs at Praxis Biologics. Prior to 1987, Dr. Top served for 21 years in the U.S. Army Medical Research and Development Command ultimately as Director and Commandant, Walter Reed Army Institute of Research from 1983-1987. Dr. Top is a pediatrician with research interests in infectious diseases and vaccines; he holds a Doctorate of Medicine cum laude and a Bachelor of Science degree in biochemistry from Yale University. Dr. Top is a member of the Board of Directors of Applied Genetics Technologies Corporation and GlycoMimetics Incorporated, in addition to VaxInnate Corporation.
Gregory Weinhoff, M.D.
Dr. Weinhoff is a Partner at Collinson, Howe & Lennox (CHL). Dr. Weinhoff served as founding CEO of Amicus Therapeutics. Previously, Dr. Weinhoff was a Senior Associate at Whitney & Co. where he concentrated on private equity investments in healthcare technology and services companies. While attending medical school and business school, he was an independent consultant to the Fidelity Select Biotechnology fund. Prior to his graduate training, Dr. Weinhoff was a financial analyst in the Healthcare Corporate Finance Group at Morgan Stanley & Co. where he worked on financings and M&A assignments for a number of biotechnology, pharmaceutical, and healthcare services clients. Dr. Weinhoff is presently a director of American Renal Associates, LLC., Amicus Therapeutics, Inc., and MedMark Services, Inc. Dr. Weinhoff is a graduate of Harvard College, Harvard Medical School and Harvard Business School, where he was a Baker Scholar.
Alan Shaw, Ph.D.
Dr. Shaw joined VaxInnate from the Merck Vaccine Research Division where he was Executive Director of MVD’s Public Policy, Public Health and Medical Affairs Department. Prior to this, he was the Executive Director of Virus & Cell Biology at Merck Research Laboratories, responsible for all the aspects of live virus vaccine research, as well as technical aspects of development and production. His responsibilities covered research and early development of recombinant protein-based vaccines. Dr. Shaw was instrumental in the development of a combination measles-mumps-rubella-varicell vaccine (ProQuad®), a live oral rotavirus vaccine, (RotaTeq®), human papillomavirus vaccine (Gardasil®), and the candidate zoster vaccine (Zostavax®) as well as numerous early-stage experimental vaccines. He has over 15 years of experience in the development, testing manufacturing, and implementation of vaccines in the United States, Europe and in international programs. Prior to joining Merck, Dr. Shaw worked on vaccines for hepatitis B and Plasmodium falciparum as well as cytokines, cell trafficking and natural inhibitors of inteleukin-1 at Biogen, SA in Geneva, Switzerland.
A Feinstein Kean Healthcare Site